Technical Analysis for MNTA - Momenta Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade B 12.02 1.86% 0.22
MNTA closed up 1.86 percent on Friday, August 16, 2019, on 82 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Up
See historical MNTA trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Overbought Stochastic Strength 0.00%
50 DMA Support Bullish 1.86%
Inside Day Range Contraction 1.86%
Overbought Stochastic Strength 1.86%
50 DMA Support Bullish 3.98%
Overbought Stochastic Strength 3.98%
NR7 Range Contraction 1.26%
NR7-2 Range Contraction 1.26%
Overbought Stochastic Strength 1.26%

Older signals for MNTA ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Momenta Pharmaceuticals, Inc., a biotechnology company, engages in the structural characterization, process engineering, and biologic systems analysis of complex molecules. Its complex molecules include polysaccharides, polypeptides, and proteins and antibodies. The company's complex generics programs comprise Enoxaparin sodium injection, a generic version of Lovenox that is used for the prevention and treatment of deep vein thrombosis, and to support the treatment of acute coronary syndromes; and M356, a generic version of Copaxone, which is a glatiramer acetate injection indicated for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis. Its biosimilars programs include M923, a biosimilar for autoimmune and inflammatory diseases; M834 for autoimmune and inflammatory diseases; and M511, a monoclonal antibody for oncology. The company's novel products comprise M402, a novel heparan sulfate mimetic that binds to various growth factors, adhesion molecules, and chemokines to inhibit tumor angiogenesis, progression, and metastasis; and the sialylation technology, which is a discovery program that is intended to modify immunoglobulin G antibodies in intravenous immunoglobulin, a drug to treat autoimmune and inflammatory diseases. It has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.
Medicine Biotechnology Immunology Antibodies Immune System Tumor Antibody Monoclonal Antibody Autoimmunity Autoimmune And Inflammatory Diseases Glycoproteins Metastasis Biosimilar Deep Vein Thrombosis Relapsing Remitting Multiple Sclerosis Acute Coronary Syndromes Immunoglobulin Therapy
Is MNTA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 29.3
52 Week Low 9.51
Average Volume 540,247
200-Day Moving Average 12.5587
50-Day Moving Average 11.5176
20-Day Moving Average 11.2135
10-Day Moving Average 11.727
Average True Range 0.5241
ADX 16.93
+DI 19.1946
-DI 15.8042
Chandelier Exit (Long, 3 ATRs ) 10.5577
Chandelier Exit (Short, 3 ATRs ) 11.0823
Upper Bollinger Band 12.6185
Lower Bollinger Band 9.8085
Percent B (%b) 0.79
BandWidth 25.059081
MACD Line 0.1715
MACD Signal Line 0.0599
MACD Histogram 0.1116
Fundamentals Value
Market Cap 886.99 Million
Num Shares 73.8 Million
EPS -0.64
Price-to-Earnings (P/E) Ratio -18.78
Price-to-Sales 9.20
Price-to-Book 2.70
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 12.47
Resistance 3 (R3) 12.44 12.26 12.40
Resistance 2 (R2) 12.26 12.15 12.28 12.37
Resistance 1 (R1) 12.14 12.07 12.20 12.17 12.34
Pivot Point 11.96 11.96 11.99 11.98 11.96
Support 1 (S1) 11.84 11.85 11.90 11.87 11.70
Support 2 (S2) 11.66 11.77 11.68 11.67
Support 3 (S3) 11.54 11.66 11.65
Support 4 (S4) 11.57